Hemant Taneja

There we go.

Your turn.

All right, I'll do it.

But by the way, the new ones aren't much better, the form factor, but the utility isn't there.

So when you look at it, today's version of this is what this was.

Yes, I agree.

I think it's very likely because the challenge with this is how can you actually manufacture those nano devices where you can take really low volumes and be accurate and measure these things?

Technology wasn't there.

So when you're going back to our hardware manufacturing innovations, I think they will catch on to enable this.

And you want this.

You want this to be that you can have real-time diagnostics, think about a modern physical, and be much more preemptive about healthcare.

Like pervasive, effective capabilities like this, these endpoints will be useful for that.

Obviously, consumer-led healthcare and the Theranos vision.

I think there's a growing movement around longevity.

It's become a cultural phenomenon.

And so that's, first of all, the fact that consumers are propensity to pay.

We have a company called Rowe, for example, that focuses on GLP-1s.

Because there's that propensity, it drives innovation to create more products like this that are focused on keeping you healthy.

I just started out of college.

One of the very first apps that was non-email on this, we wrote that.